ArticleFrontiers in aging neuroscience2025
The impact of ondansetron on clinical outcomes in cranial surgery patients: a propensity-matched analysis of retrospective data.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cranial surgery represents a substantial public health challenge, characterized by intricate postoperative management that can complicate patient recovery. This study investigates the effect of ondansetron, a serotonin receptor antagonist, on clinical outcomes in adult patients undergoing cranial surgery, addressing the uncertainty surrounding its impact on postoperative complications. Methods: Utilizing a retrospective cohort design, we analyzed data from 2,297 eligible patients, segregating them into ondansetron-treated and control groups, while applying propensity score matching to harmonize baseline characteristics. The primary outcomes assessed were 28-day and 90-day mortality, evaluated using multivariable Cox regression and Kaplan-Meier analysis. Results: After matching, 905 well-balanced pairs were included. Ondansetron administration was associated with significantly lower 28-day mortality (hazard ratio [HR] = 0.69, 95% confidence interval [CI]: 0.52-0.92; Conclusion: The administration of ondansetron in cranial surgery patients with a Glasgow Coma Scale score exceeding eight is associated with a significant reduction in short-term mortality, suggesting that ondansetron could be a viable therapeutic strategy to enhance postoperative recovery outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.